TL;DR
This study reveals that extracellular vesicles (EVs) derived from human placental mesenchymal stem cells (P-MSCs) can significantly accelerate diabetic wound healing. They achieve this by delivering miR-145-5p, which rejuvenates senescent fibroblasts by targeting CDKN1A and activating the Erk/Akt signaling pathway. This work positions P-MSC-EVs as a promising therapeutic avenue for treating chronic diabetic wounds.
What Problem Does This Paper Address?
Diabetic patients often suffer from delayed or non-healing chronic wounds, particularly foot ulcers. This is largely due to a high-glucose (HG) microenvironment that impairs the function of human dermal fibroblasts (HDFs), leading to senescence, reduced proliferation, migration, and increased apoptosis. Conventional treatments for these wounds are frequently ineffective, increasing the risk of limb amputation. While mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have shown therapeutic potential, the specific mechanisms by which placental MSC-derived EVs (P-MSC-EVs) improve diabetic wound healing and the role of specific miRNAs within them remain unclear. This paper aims to elucidate these mechanisms, focusing on how P-MSC-EVs can counteract HG-induced fibroblast dysfunction.
Methods
The researchers employed a multi-pronged approach:
- In Vivo Studies: P-MSC-EVs were injected into full-thickness skin wounds in diabetic mice to assess their impact on wound closure rates and tissue regeneration through histological analysis.
- In Vitro Studies:
- Cell Culture: Human dermal fibroblasts (HDFs) were cultured under normal glucose (NG) and high glucose (HG) conditions to induce senescence.
- P-MSC-EV Isolation and Characterization: P-MSC-EVs were isolated using differential ultracentrifugation and characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and western blotting for EV markers (CD9, TSG101).
- EV Uptake Assay: PKH67-labeled P-MSC-EVs were used to confirm their internalization by HDFs.
- Functional Assays: The effects of P-MSC-EVs on senescent HDFs were evaluated using assays for:
- Senescence: SA-β-gal staining.
- Proliferation: EdU incorporation and CCK-8 assays.
- Cell Cycle: Flow cytometry.
- Migration: Scratch and transwell assays.
- Apoptosis: Flow cytometry.
- miRNA Analysis: miRNA microarrays and RT-qPCR were used to identify differentially expressed miRNAs in HDFs after EV treatment and to quantify miRNA levels in P-MSC-EVs.
- Mechanism Elucidation: * miRNA Interference: miR-145-5p mimics and inhibitors were used to investigate its role.
- Target Gene Identification: Small interfering RNAs (siRNAs) targeting predicted target genes (CDKN1A and CAMK1D) were employed.
- Signaling Pathway Analysis: Western blotting was used to assess the activation of the Erk/Akt signaling pathway.
- In Vivo miRNA Administration: miR-145-5p agomirs and antagomirs were administered locally to diabetic wounds to confirm the in vivo role of miR-145-5p.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- P-MSC-EVs as potent wound healers: The study provides strong evidence that P-MSC-EVs can significantly accelerate diabetic wound closure and improve tissue quality, reducing scar formation.
- miR-145-5p is the key player: The research pinpoints miR-145-5p as a crucial cargo within P-MSC-EVs responsible for their therapeutic effects on senescent fibroblasts. Its enrichment in P-MSC-EVs is a novel finding.
- Rejuvenating senescent fibroblasts: P-MSC-EVs, through miR-145-5p, can reverse key aspects of HG-induced fibroblast senescence, restoring their proliferative, migratory, and anti-apoptotic functions.
- CDKN1A as a direct target: The study identifies CDKN1A (cyclin-dependent kinase inhibitor 1A) as a direct target of miR-145-5p, and its downregulation is critical for the observed functional improvements.
- Erk/Akt pathway activation: The mechanism involves miR-145-5p targeting CDKN1A to activate the Erk/Akt signaling pathway, a known pathway involved in cell growth and survival.
- CAMK1D is not the primary target: While CAMK1D was predicted as a target, its inhibition did not affect fibroblast function, suggesting CDKN1A is the more critical target for the observed benefits.
Key Results
- In Vivo: P-MSC-EV treatment significantly accelerated wound closure and reduced scar width in diabetic mice compared to PBS control. Histological analysis showed better collagen organization. P16INK4a (a senescence marker) was reduced in P-MSC-EV treated wound beds.
- In Vitro:
- P-MSC-EVs reduced SA-β-gal positive cells (senescence marker) in HG-induced HDFs in a dose-dependent manner.
- P-MSC-EVs enhanced proliferation, cell cycle progression (S and G2/M phases), and migration of HG-induced HDFs.
- P-MSC-EVs reduced apoptosis and increased the expression of proliferation-related proteins (Cyclin D1) and anti-apoptotic proteins (Bcl-2), while decreasing pro-apoptotic proteins (Bax).
- miR-145-5p was highly enriched in P-MSC-EVs.
- Inhibiting miR-145-5p reversed the beneficial effects of P-MSC-EVs on HDF function.
- Mimicking miR-145-5p with mimics replicated the positive effects of P-MSC-EVs.
- Knocking down CDKN1A mimicked the effects of miR-145-5p on HDF proliferation, migration, and senescence, and activated Erk/Akt signaling.
- In vivo administration of miR-145-5p agomir accelerated wound healing, reduced scar width, and decreased p16INK4a expression, similar to P-MSC-EVs.
Limitations and Future Work
- In vivo miRNA/target validation: The authors acknowledge that they did not directly measure miR-145-5p and CDKN1A expression in vivo after treatment to confirm the in vitro findings.
- Apoptosis mechanism: The study did not identify the specific target(s) of miR-145-5p responsible for its anti-apoptotic effects on HG-induced senescent HDFs.
- Transcriptional analysis: The extent of transcriptional changes in key proteins of the Erk/Akt pathway in the wound-healing model was not assessed.
- EV concentration optimization: Further experiments with higher concentrations of P-MSC-EVs could be performed to explore potential for even better regenerative effects.
- Other cell types: The study suggests investigating the effects of P-MSC-EVs on other cell types involved in wound healing.
- Therapeutic potential: The authors propose that P-MSC-EVs encapsulating therapeutic miRNAs represent a promising future therapeutic approach for diabetic wound treatment.
Summary updated